SG11202109710QA - Capsid assembly modulator solid formulation - Google Patents
Capsid assembly modulator solid formulationInfo
- Publication number
- SG11202109710QA SG11202109710QA SG11202109710QA SG11202109710QA SG 11202109710Q A SG11202109710Q A SG 11202109710QA SG 11202109710Q A SG11202109710Q A SG 11202109710QA SG 11202109710Q A SG11202109710Q A SG 11202109710QA
- Authority
- SG
- Singapore
- Prior art keywords
- solid formulation
- capsid assembly
- assembly modulator
- modulator
- capsid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2019/000231 WO2019175657A1 (en) | 2018-03-14 | 2019-03-13 | Capsid assembly modulator dosing regimen |
| EP2019056348 | 2019-03-13 | ||
| US16/352,754 US10973801B2 (en) | 2018-03-14 | 2019-03-13 | Capsid assembly modulator dosing regimen |
| EP19197566 | 2019-09-16 | ||
| PCT/EP2020/056991 WO2020183020A1 (en) | 2019-03-13 | 2020-03-13 | Capsid assembly modulator solid formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109710QA true SG11202109710QA (en) | 2021-10-28 |
Family
ID=72427202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109710Q SG11202109710QA (en) | 2019-03-13 | 2020-03-13 | Capsid assembly modulator solid formulation |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3937928A1 (en) |
| JP (1) | JP2022524819A (en) |
| KR (1) | KR20210137484A (en) |
| CN (1) | CN113557016A (en) |
| AU (1) | AU2020235442A1 (en) |
| BR (1) | BR112021017525A2 (en) |
| CA (1) | CA3132095A1 (en) |
| CR (1) | CR20210481A (en) |
| EC (1) | ECSP21067052A (en) |
| IL (1) | IL286209A (en) |
| JO (1) | JOP20210250A1 (en) |
| MA (1) | MA55280A (en) |
| MX (1) | MX2021011030A (en) |
| PE (1) | PE20212107A1 (en) |
| SG (1) | SG11202109710QA (en) |
| WO (1) | WO2020183020A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201808949SA (en) | 2016-04-15 | 2018-11-29 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
| KR20200131816A (en) * | 2018-03-14 | 2020-11-24 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Capsid assembly modulator dosing regimen |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3603B1 (en) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| KR20200131816A (en) * | 2018-03-14 | 2020-11-24 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Capsid assembly modulator dosing regimen |
-
2020
- 2020-03-13 JP JP2021554750A patent/JP2022524819A/en active Pending
- 2020-03-13 MX MX2021011030A patent/MX2021011030A/en unknown
- 2020-03-13 KR KR1020217031285A patent/KR20210137484A/en unknown
- 2020-03-13 MA MA055280A patent/MA55280A/en unknown
- 2020-03-13 BR BR112021017525A patent/BR112021017525A2/en not_active IP Right Cessation
- 2020-03-13 EP EP20709618.1A patent/EP3937928A1/en not_active Withdrawn
- 2020-03-13 WO PCT/EP2020/056991 patent/WO2020183020A1/en unknown
- 2020-03-13 SG SG11202109710Q patent/SG11202109710QA/en unknown
- 2020-03-13 AU AU2020235442A patent/AU2020235442A1/en not_active Abandoned
- 2020-03-13 CR CR20210481A patent/CR20210481A/en unknown
- 2020-03-13 CN CN202080020501.XA patent/CN113557016A/en active Pending
- 2020-03-13 CA CA3132095A patent/CA3132095A1/en not_active Abandoned
- 2020-03-13 JO JOP/2021/0250A patent/JOP20210250A1/en unknown
- 2020-03-13 PE PE2021001464A patent/PE20212107A1/en unknown
-
2021
- 2021-09-09 IL IL286209A patent/IL286209A/en unknown
- 2021-09-10 EC ECSENADI202167052A patent/ECSP21067052A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020235442A1 (en) | 2021-08-12 |
| PE20212107A1 (en) | 2021-11-04 |
| CN113557016A (en) | 2021-10-26 |
| JOP20210250A1 (en) | 2023-01-30 |
| JP2022524819A (en) | 2022-05-10 |
| CA3132095A1 (en) | 2020-09-17 |
| CR20210481A (en) | 2021-10-25 |
| WO2020183020A1 (en) | 2020-09-17 |
| MX2021011030A (en) | 2021-10-13 |
| MA55280A (en) | 2022-01-19 |
| KR20210137484A (en) | 2021-11-17 |
| ECSP21067052A (en) | 2021-11-18 |
| BR112021017525A2 (en) | 2021-11-23 |
| EP3937928A1 (en) | 2022-01-19 |
| IL286209A (en) | 2021-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3897522A4 (en) | Microcapsule compositions | |
| GB2583614B (en) | Hepatitis B capsid assembly modulators | |
| HUE061394T2 (en) | Tmem16a modulators | |
| IL292156A (en) | Substituted azacyles as trmp8 modulators | |
| GB201813855D0 (en) | Modulator assembly | |
| GB2596231B (en) | Modulators | |
| IL277262A (en) | Capsid assembly modulator dosing regimen | |
| IL286209A (en) | Capsid assembly modulator solid formulation | |
| GB201904338D0 (en) | Fluorouracil-containing formulations | |
| PT4045038T (en) | New formulations | |
| EP3886820B8 (en) | Capsule formulations | |
| IL290356A (en) | Larazotide formulations | |
| IL284691A (en) | Formulations | |
| GB2585587B (en) | Modulators | |
| EP3718568A4 (en) | Activity modulator | |
| GB2589428B (en) | Linearized modulator | |
| GB201918974D0 (en) | Gpr52 modulator compounds | |
| GB201918992D0 (en) | GPR52 modulator compounds | |
| GB201916298D0 (en) | GPR52 modulator compounds | |
| GB201903889D0 (en) | PDE5 modulator formulations | |
| GB201804544D0 (en) | PDE5 Modulator formulations | |
| GB201911063D0 (en) | Formulations | |
| GB201910093D0 (en) | New formulations | |
| GB201910092D0 (en) | New formulations | |
| GB201905105D0 (en) | Formulations |